An Evaluation of the Swissmedic Regulatory Framework for New Active Substances.
Magda BujarSimon Andreas Dalla Torre di SanguinettoAdem KermadClaus BolteNeil McAuslanePublished in: Therapeutic innovation & regulatory science (2023)
These observations represent an important analysis of Swissmedic regulatory activity timelines, demonstrate the impact of process improvements, and emphasise the importance of measuring timelines. Swissmedic will continue to expedite its processes also by promoting international collaborations with like-minded authorities.
Keyphrases